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tion3,4 and glucose metabolism.5 In accordance with
this, we have recently shown that captopril improves
oxygen and glucose extraction during blood reperfusion
of isolated pig hearts.6 It remains unknown, however,
whether the beneficial effect of ACE inhibition takes
place during cardioplegic storage, during reperfusion,
A ngiotensin-converting enzyme (ACE) inhibitionimproves the cardioprotective properties of cardio-
plegic solutions, resulting in improved myocardial
function during postcardioplegic reperfusion.1,2 It has
been proposed that the underlying mechanism may
involve modulation of myocardial oxygen consump-
Objective: We sought to evaluate the effects of captopril on glucose-related
metabolism during hypothermic cardioplegic storage and subsequent reper-
fusion.
Methods: We compared hearts from control pigs with hearts from pigs treat-
ed with increasing oral doses of captopril for 3 weeks (12.5-150 mg daily),
an intravenous bolus (25 mg) before operation, and captopril-containing car-
dioplegic solution (1 mg/L). The hearts were excised after infusion of cold
crystalloid cardioplegic solution and stored in saline solution (4°C-6°C). In
one series we studied myocardial blood flow and arteriovenous differences
in oxygen, glucose, lactate, glutamate, and alanine during 60 minutes of
postcardioplegic blood reperfusion. In this series captopril-treated hearts
were reperfused with captopril-containing blood (1 mg/L). In another series
we obtained biopsy specimens from the left ventricle throughout 30 hours of
hypothermic cardioplegic storage and monitored tissue content of energy-
rich phosphates, glycogen, glutamate, and alanine.
Results: Captopril increased glutamate and alanine release 11- to 17-fold at
the start of reperfusion (P < .001 ). Furthermore, captopril increased myocar-
dial oxygen and glucose uptake during reperfusion (P < .001 for both),
whereas lactate release and myocardial blood flow were unaffected by cap-
topril. At the start of reperfusion, there was a positive correlation between
glutamate release and glucose uptake in captopril-treated hearts (r = 0.66, P
= .05). We found no statistically significant differences between captopril
and control hearts in tissue content of adenosine triphosphate, glycogen, glu-
tamate, alanine, or lactate during 30 hours of cardioplegic storage.
Conclusions: The metabolic effects of captopril are strictly related to reper-
fusion, during which oxidative metabolism of glucose is improved. The cap-
topril-induced increase in glutamate and alanine release at the start of reper-
fusion after cardioplegic storage may reflect a switch in metabolism of
glucose-related amino acids. (J Thorac Cardiovasc Surg 2000;119:1030-8)
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or both. Furthermore, the metabolic pathways involved
are not fully elucidated. Glutamate is closely related to
glucose metabolism during ischemia,7,8 and improved
oxidative metabolism may thus affect myocardial han-
dling of glutamate.
We studied whether captopril affects myocardial
metabolism during cardioplegic storage, postcardio-
plegic reperfusion, or both. We hypothesized that cap-
topril may affect glucose-related amino acid metabo-
lism during cardioplegic storage, postcardioplegic
reperfusion, or both.
Materials and methods
Animal preparation. We used hearts from 34 domestic
pigs (Danish and Yorkshire Landrace) of both sexes (heart
weight, 0.35 ± 0.02 kg). The study was approved and found
to be in accordance with Danish standards for the care and
use of laboratory animals and animal care and procedures
conformed to the guidelines established by the US National
Institutes of Health (Guide for the Care and Use of
Laboratory Animals; National Institutes of Health publication
No. 85-23, revised 1985).
The animals were premedicated with intramuscular mid-
azolam (Dormicum, 0.5 mg/kg) and ketamine (Ketalar, 10
mg/kg) followed by intravenous ketamine (5 mg/kg) before
orotracheal intubation. Pigs were anaesthetized with
halothane 1% to 2% and placed on positive-pressure ventila-
tion (N2O/O2 mixture 2:1, Engström Respirator System 300;
Lab Medical AB, Bromma, Sweden).
After median sternotomy and systemic heparinization
(200 U/kg), the pericardium was opened, a vent was intro-
duced into the left ventricle through the left atrial
appendage, and both caval veins were clamped. After aor-
tic crossclamping, 1 L of Bretschneider’s procaine contain-
ing solution No. 3 (sodium, 12 mmol/L; potassium, 10
mmol/L; magnesium, 1 mmol/L; procaine, 7.3 mmol/L;
chloride, 31.3 mmol/L; and mannitol, 239 mmol/L; oxy-
genated solution with 12.5 mL of NaOH added to obtain a
pH of 7.4) was infused antegradely through the aortic root.
After infusion, the hearts were excised and immersed in 0.5
L of cold (4°C-6°C) heparinized saline solution. The hearts
were kept at this temperature during a hypothermic cardio-
plegic storage (HCS) period of either 6 or 30 hours.
Study series. We compared hearts from control pigs with
hearts from captopril-treated pigs in two distinct study series.
Hearts were randomized within, but not between, study series.
In one series we studied cardiac hemodynamics and metab-
olism during 60 minutes of blood reperfusion subsequent to
6 hours of HCS.
Control pigs (n = 8). After cardioplegic arrest, hearts were
excised and subjected to 6 hours of HCS. Subsequently, the
hearts were reperfused with blood in a modified Langendorff
model.
Captopril-treated pigs (n = 9). Animals were pretreated
with increasing oral doses of captopril (Capoten) for 3 weeks.
They received 12.5 mg once a day on day 1, increasing to
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37.5 mg 3 times a day on day 7, and thereafter to 50 mg 3
times daily for the remaining 2 weeks. Before the operation,
an intravenous bolus of captopril (25 mg) was given. In addi-
tion, captopril-containing (1 mg/L) cardioplegic solution was
infused before exposure to 6 hours of HCS and subsequent
reperfusion with captopril-containing blood (1 mg/L) in the
Langendorff model.
Fig 1. Net glutamate and glucose flux in captopril-treated
(n = 9) and control (n = 8) hearts at the start of reperfusion
(0 minutes). Note that the net glucose flux was 0.0 mmol/min
in 3 control animals. At the start of reperfusion, captopril
increased glutamate release approximately 11-fold (‡P <
.001) and glucose uptake 5-fold (†P = .02).
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Table I. Blood flow and metabolic variables (net glucose, lactate, oxygen, glutamate, and alanine flux across the 
myocardium) in captopril-treated (n = 9) and control (n = 8) hearts during 60 minutes of blood reperfusion in a 
modified Langendorff model
Reperfusion time (min)
Variable Group 0 4 8 12
Blood flow (L/min) Captopril 0.58 ± 0.05 0.57 ± 0.06 0.58 ± 0.09 0.62 ± 0.10
Control 0.53 ± 0.07 0.53 ± 0.07 0.56 ± 0.10 0.63 ± 0.11
Glucose flux (mmol/min) Captopril 0.25 ± 0.12† 0.04 ± 0.03 0.06 ± 0.04 0.21 ± 0.15*
Control 0.05 ± 0.08 0.04 ± 0.05 0.06 ± 0.06 0.13 ± 0.09
Lactate flux (mmol/min) Captopril –0.90 ± 0.32 –0.37 ± 0.17 –0.35 ± 0.21 –0.30 ± 0.19
Control –0.80 ± 0.25 –0.37 ± 0.17 –0.22 ± 0.20 –0.23 ± 0.11
Oxygen flux (mL/min) Captopril 18.68 ± 10.15 32.61 ± 7.42† 33.39 ± 9.35† 28.96 ± 9.21†
Control 20.48 ± 5.56 20.95 ± 4.49 22.59 ± 6.49 17.87 ± 4.26
Glutamate flux (mmol/min) Captopril –98.75 ± 53.47‡ –2.65 ± 1.70 –2.39 ± 1.84 –3.92 ± 1.42
Control –8.69 ± 8.05 –2.23 ± 2.24 –1.59 ± 1.27 –2.31 ± 1.98
Alanine flux (µmol/min) Captopril –50.62 ± 54.96‡ –5.39 ± 2.29 –5.98 ± 3.51 –6.73 ± 1.39
Control –2.86 ± 1.95 –3.15 ± 1.61 –4.33 ± 1.31 –6.40 ± 1.72
Values shown are means ± SD. P values indicate differences between captopril-treated and control hearts during reperfusion. Because of nonhomogeneous data at
the start of reperfusion, glutamate and alanine flux were compared from 4 minutes of reperfusion.
*†Significant differences during reperfusion (*P < .05, †P < .02; modified Bonferroni post hoc test).
‡Significant differences between captopril-treated and control hearts at the start of reperfusion (P < .001; nonparametric test).
In another series we studied myocardial energy stores and
metabolites during 30 hours of HCS.
Control pigs (n = 8). Cardioplegic arrest was induced, and
the hearts were subjected to 30 hours of HCS. The hearts
were not reperfused.
Captopril-treated pigs (n = 9). Animals were premedicat-
ed with captopril as in the previous study series, and cardio-
plegic arrest was induced with captopril-containing cardio-
plegic solution. The hearts were subjected to 30 hours of
HCS without subsequent reperfusion.
Reperfusion 
Hearts allocated to 6 hours of HCS and 60 minutes of
reperfusion. After 6 hours of HCS, the hearts were reperfused
in a modified Langendorff perfusion model with blood-
Ringer chloride solution (1:1), as previously described.9,10
The hearts were prepared for reperfusion as described.9
Electrical defibrillation was performed after 10 minutes of
reperfusion because of ventricular fibrillation at the begin-
ning of reperfusion. At this time, the hearts had reached a
temperature necessary to obtain regular contractions after
defibrillation. Left ventricular function was monitored con-
tinuously during reperfusion, and myocardial blood flow and
content of oxygen, lactate, glucose, glutamate, and alanine in
arterial and coronary sinus blood were measured simultane-
ously at the start of reperfusion and after 4, 8, 12, 18, 25, 40,
and 60 minutes of reperfusion.
Measurements. Left ventricular peak systolic pressure,
end-diastolic pressure, and the first derivative of the left ven-
tricular pressure (dP/dt) were recorded continuously during
the reperfusion period.10 Developed left ventricular pressure
was calculated as the difference between left ventricular peak
systolic pressure and end-diastolic pressure.
Myocardial blood flow was measured directly by collecting
the blood perfusate from the right atrium during reperfusion.
Lactate was analyzed in whole blood,11 and glucose,12
glutamate, and alanine13 were analyzed in plasma. Net
metabolite flux across the myocardium was calculated as
aorta-coronary sinus concentration differences multiplied by
myocardial blood flow for whole blood analyses corrected by
multiplying metabolite flux with 1 – hematocrit for plasma
analyses. A negative net flux reflects release, and a positive
net flux reflects uptake of a metabolite. Blood oxygen satura-
tion and pressure were measured with a blood gas analyzer
(Copenhagen ABL, Copenhagen, Denmark). Myocardial
oxygen uptake (in milliliters per minute) was calculated as
previously described.10
Prolonged HCS
Hearts allocated to 30 hours of HCS. During 30 hours of
HCS, we harvested transmyocardial biopsy specimens from
the anterior wall of the left ventricle by using a Tru-Cut biop-
sy needle (Baxter Healthcare Corporation, Deerfield, Ill).
Samples were obtained at 15 minutes and 1, 3, 6, 12, 18, 22,
24, 27, and 30 hours of HCS.
Measurements. The tissue samples were plunged into liq-
uid nitrogen, and metabolites were extracted by using 500 µL
of ice-cold 0.42 mmol/L perchloric acid. The samples were
homogenized mechanically on ice-bath with a Teflon pestle
and centrifuged at 4°C.14 Tissue concentrations of lactate,11
alanine, and glutamate13 were determined enzymatically in
the clear supernatant, as described for the blood samples.
High-energy phosphates were analyzed by using high-perfor-
mance chromatography (Shimadzu, Kyoto, Japan).14 Tissue
glycogen content was determined by using the filter paper
technique.15
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Statistical analysis. All results are presented as means ±
SD. Data were tested for normality and homogeneity of vari-
ance. When statistically insignificant, variables were consid-
ered unchanged or unaffected.
Hearts allocated to HCS and reperfusion. Functional
variables were compared from 12 minutes of reperfusion
when all hearts were beating to the end of reperfusion.
Blood flow and glucose, lactate, and oxygen flux were
compared from the start to the end of reperfusion.
Glutamate and alanine flux were compared from 4 minutes
to the end of reperfusion. We used analysis of variance
(ANOVA) for repeated measurements with the BMDP
computer program 5V (“unbalanced repeated-measures
models with structural covariance matrices”; BMDP
Software, Los Angeles, Calif). If significant, the post hoc
modified t test, according to the method of Bonferroni, was
used to localize statistical differences. Glutamate and ala-
nine flux at the start of reperfusion were compared by non-
parametric statistics. Correlation between variables was
analyzed by linear regression.
Hearts allocated to prolonged HCS. Comparisons were
made over 30 hours of HCS by using ANOVA for repeated
measurements.
Results
Intraoperatively, left ventricular function was simi-
lar in captopril-treated and control hearts (developed
left ventricular pressure, 67 ± 14 vs 76 ± 14 mm Hg,
P = .2; contractility, 700 ± 182 vs 794 ± 182 mm Hg/s, P
= .3; relaxation, 952 ± 337 vs 1167 ± 366 mm Hg/s, P =
.1; heart rate, 78 ± 15 vs 80 ± 14 beats/min, P = .6).
Effects of captopril on myocardial function and
metabolism during 60 minutes of reperfusion after
6 hours of hypothermic cardioplegic storage
Left ventricular function. Developed left ventricular
pressure was increased in captopril-treated hearts during
reperfusion (151 ± 16 vs 134 ± 19 mm Hg, P = .02). The
same was the case for left ventricular relaxation (–dP/dt,
1508 ± 383 vs 1307 ± 384 mm Hg/s, P = .04), whereas
captopril decreased heart rate (110 ± 27 vs 133 beats/min,
P = .04). We found no differences in rate pressure prod-
uct (16,610 ± 1652 vs 17,822 ± 1827 mm Hg/min, P =
.6), contractility (+dP/dt; 1668 ± 347 vs 1656 ± 346 mm
Hg/s, P = .9), or left ventricular end-diastolic pressure
(11.9 ± 3.3 vs 11.3 ± 3.4 mm Hg, P = .8) between capto-
pril-treated and control hearts during reperfusion.
Myocardial blood flow. We observed no differences
in myocardial blood flow between captopril-treated
hearts and control hearts during 60 minutes of reperfu-
sion (Table I).
Glucose uptake. Glucose uptake was increased in
captopril-treated hearts during reperfusion (P < .001),
despite similar myocardial blood flow in the two
study groups (Table I). In both captopril-treated and
control hearts, glucose uptake showed a characteristic
biphasic pattern with a high initial uptake at the start
of reperfusion followed by a decline after 4 minutes
of reperfusion. This was followed by a second
increase after defibrillation (12-18 minutes of reper-
fusion). This pattern was most pronounced in capto-
pril-treated hearts, and the effect of captopril on glu-
Reperfusion time (min)
18 25 40 60 P values (ANOVA)
0.67 ± 0.09 0.65 ± 0.10 0.64 ± 0.09 0.64 ± 0.10 .9
0.65 ± 0.10 0.65 ± 0.12 0.64 ± 0.12 0.66 ± 0.13
0.19 ± 0.04* 0.14 ± 0.10* 0.09 ± 0.07 0.08 ± 0.04 .001
0.08 ± 0.03 0.04 ± 0.06 0.11 ± 0.05 0.07 ± 0.06
–0.05 ± 0.16 –0.05 ± 0.18 0.03 ± 0.15 0.01 ± 0.29 .6
0.02 ± 0.17 –0.12 ± 0.36 0.08 ± 0.16 0.06 ± 0.21
28.23 ± 8.66† 24.86 ± 9.05† 25.04 ± 11.33† 15.59 ± 5.80 .001
17.12 ± 3.66 15.97 ± 2.79 14.39 ± 3.30 11.28 ± 1.91
–0.88 ± 1.71 –1.17 ± 0.99 –0.56 ± 1.64 –0.83 ± 1.39 .7
–1.32 ± 1.32 –0.67 ± 1.42 –0.10 ± 1.73 –0.14 ± 0.90
–2.90 ± 3.00 –3.63 ± 3.08 –4.39 ± 2.25 –5.28 ± 5.95 .9
–5.15 ± 3.65 –5.75 ± 3.42 –4.84 ± 3.20 –4.33 ± 3.59
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cose uptake was most pronounced at the start of reper-
fusion (P = .02; Fig 1 and Table I) and after defibril-
lation (P = .04; Table I).
Lactate release. Myocardial lactate release was unaf-
fected by captopril during reperfusion (Table I). In both
captopril-treated and control hearts, lactate release was
high at the beginning of reperfusion, decreased during
the first 25 minutes of reperfusion, and then ceased.
Oxygen uptake. Oxygen uptake data is shown in
Table I. At the beginning of reperfusion (0 minutes),
we observed no difference in oxygen uptake between
captopril-treated and control hearts (18.68 ± 10.15 vs
20.48 ± 5.56 mL/min, P = .3). During the first 4 min-
utes of reperfusion, however, oxygen uptake
increased in captopril-treated hearts (from 18.68 ±
10.15 to 32.61 ± 7.42 mL/min, P = .01), whereas no
increase was observed in control hearts (20.48 ± 5.56
vs 20.95 ± 4.49 mL/min, P = .6). During the remain-
ing reperfusion period, the difference in oxygen
uptake between captopril-treated and control hearts
was maintained (P < .001).
Glutamate release. Captopril increased glutamate
release 11-fold at the start of reperfusion (P < .001; Fig
1 and Table I). Glutamate release declined in both cap-
topril-treated and control hearts from the start to 4 min-
utes of reperfusion. This was most pronounced in cap-
topril-treated hearts (captopril-treated hearts, from
98.75 ± 53.47 to 2.65 ± 1.70 µmol/min [P < .001], vs
control hearts, from 8.69 ± 8.05 to 2.23 ± 2.24
µmol/min [P = .01]).
Alanine release. Captopril increased alanine release
17-fold at the start of reperfusion (P < .001; Table I).
The release pattern was similar in the two groups, but
like glutamate, the change in release from the start to 4
minutes of reperfusion was most pronounced in capto-
pril-treated hearts.
Relation between glucose uptake and glutamate
release at the start of reperfusion. In captopril-treated
hearts there was a linear relationship between glutamate
release and glucose uptake (r = 0.66, P = .05). This rela-
tionship was not observed in control hearts (Fig 2). 
Other relations between glucose-related metabolites.
In captopril-treated hearts a positive correlation was
found between glutamate and alanine release at the start
of reperfusion (r = 0.85, P = .01), whereas no relation-
ship was observed between the release of lactate- and
glucose-related amino acids (r = 0.27, P = .5 for lactate
vs glutamate; r = 0.58, P = .1 for lactate vs alanine).
Effects of captopril on myocardial content of
metabolites during 30 hours of HCS (Table II). We
found no difference in heart weight between captopril-
treated hearts and control hearts after 30 hours of HCS
(280 ± 31 vs 273 ± 16 g, P = .6).
Glycogen content. Captopril did not affect glycogen
content during 30 hours of HCS. Myocardial levels of
glycogen were high at the beginning of HCS in both
captopril-treated and control hearts and declined con-
tinuously during the HCS period.
Lactate content. We found no difference in lactate
accumulation between captopril-treated and control
hearts. In both groups tissue levels of lactate increased
during 30 hours of HCS.
Adenosine triphosphate content. Captopril had no
effect on myocardial content of adenosine triphosphate
during 30 hours of HCS. Tissue adenosine triphosphate
content declined continuously during the HCS period.
Glutamate content. We found no differences in
myocardial glutamate content between captopril-treat-
ed and control hearts. Myocardial levels of glutamate
declined during 30 hours of HCS in both groups.
Alanine content. Captopril did not affect myocardial
content of alanine during 30 hours of HCS. We
Table II. Tissue content of metabolic variables (glycogen, ATP, glutamate, and alanine) in captopril-treated (n = 9)
and control (n = 8) hearts during 30 hours of HCS
HCS time (h)
Variable Group 0.25 6 30 P values (ANOVA)
Glycogen content (nmol/mg) Captopril 29.56 ± 4.98 21.78 ± 2.22 8.78 ± 3.73 .5
Control 27.71 ± 5.28 20.00 ± 4.31 9.25 ± 3.45
Lactate content (nmol/mg) Captopril 1.73 ± 2.42 13.09 ± 3.61 25.53 ± 2.91 .8
Control 0.71 ± 0.70 10.94 ± 2.29 25.53 ± 2.90
ATP content (nmol/mg) Captopril 3.63 ± 0.70 2.70 ± 0.61 0.82 ± 0.30 .5
Control 3.56 ± 0.56 2.53 ± 0.34 0.82 ± 0.27
Glutamate content (nmol/mg) Captopril 3.50 ± 0.95 2.29 ± 0.51 1.39 ± 0.35 .7
Control 3.28 ± 0.54 2.39 ± 0.58 1.46 ± 0.47
Alanine content (nmol/mg) Captopril 0.83 ± 0.43 1.82 ± 0.46 2.59 ± 0.65 .1
Control 0.45 ± 0.45 1.45 ± 0.46 2.34 ± 0.59
Values are shown as means ± SD. P values indicate differences between captopril-treated and control hearts during the period of HSC.
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observed an increase in tissue alanine content in both
captopril-treated and control hearts during storage.
Relation between glucose-related amino acids. In
both captopril-treated and control hearts, there was a
linear relationship between tissue content of glutamate
and alanine (r = 0.96, P < .001).
Discussion
The main finding of the present study is a captopril-
induced release of glutamate and alanine at the start of
reperfusion after 6 hours of hypothermic cardioplegic
storage. In addition, captopril increased glucose and
oxygen uptake without influencing lactate release.
Increased glutamate release and glucose uptake were
most pronounced at the start of reperfusion, at which
time the two variables were correlated in a linear fash-
ion. We therefore suggest that increased glutamate
release in this study is a consequence of an abrupt cap-
topril-induced shift to oxidative glucose metabolism at
the start of reperfusion after cardioplegic storage.
Because we observed no differences in tissue content of
glucose-related metabolites between captopril-treated
and control hearts during 30 hours of HCS, the study
further demonstrates that the metabolic effects of cap-
topril are related to reperfusion rather than the cardio-
plegic storage.
Effects of ACE inhibition on functional recovery
during postcardioplegic reperfusion. ACE inhibition
improves the cardioprotective effects of crystalloid car-
dioplegic solutions.1,2 In accordance with this, ACE
inhibition resulted in improved developed left ventricu-
lar pressure and relaxation during postcardioplegic
reperfusion in our study. However, in contrast to previ-
ous studies in isolated hearts,2,16,17 we found no effect
of captopril on myocardial blood flow, indicating that
the captopril-induced alterations in myocardial
metabolite exchange are independent of myocardial
blood flow.
Effects of ACE inhibition on glutamate and glu-
cose metabolism during postcardioplegic reperfu-
sion. Glutamate plays an important role for energy
metabolism in the ischemic myocardium (Fig 3, A).18,19
Clinical trials demonstrating increased glutamate
uptake in patients with coronary artery disease20,21 yield
additional support for the importance of glutamate
under conditions of ischemia. These studies showed a
close relationship between myocardial carbohydrate
metabolism and glutamate exchange by a positive cor-
relation between glucose and glutamate uptake in
patients with ischemic heart disease.21 In addition, we
have demonstrated that glutamate enrichment during
reperfusion improves postcardioplegic recovery.22 In
the present study, captopril induced a massive glutamate
release during postcardioplegic reperfusion. We have
previously observed a substantial loss of glutamate from
pig hearts at the start of reperfusion after cold crystal-
loid cardioplegia.23 However, the glutamate release in
captopril-treated hearts increased approximately 11-
fold compared with that found in control hearts.
Our findings suggest that the role of glutamate for
energy generating metabolism after captopril treatment
is minor during reperfusion when myocardial oxygen
and glucose availability is restored (Fig 3, B). We sug-
gest that the underlying mechanism is the superiority of
glucose over glutamate for replenishment of citric acid
cycle intermediates when excess glucose and oxygen is
Fig 2. Correlation between glutamate release and glucose uptake in captopril-treated hearts (n = 9) at the start of
reperfusion. There was a linear relationship between the two variables in captopril-treated hearts (r = 0.66, P =
.05), which could not be found in control hearts.
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available. The necessity of glutamate for anaplerosis of
the citric acid cycle seems to cease under these condi-
tions. This explains not only the glutamate release in
captopril-treated hearts but also the linear relationship
between glucose uptake and glutamate release.
Myocardial glucose uptake is enhanced up to 3-fold
during reperfusion after hypoxia.24,25 Glucose is trans-
formed to both acetyl coenzyme A and the citric acid
cycle intermediate oxaloacetate (Fig 3, B).26 In capto-
pril-treated hearts we found increased uptake of glu-
cose, which supplies the citric acid cycle with both
acetyl coenzyme A and oxaloacetate, enabling the heart
to oxidize larger amounts of glucose. Thus the
improvement in developed left ventricular pressure and
relaxation seems to be caused by a captopril-induced
enhancement of glucose oxidation.
Effects of captopril during prolonged cardioplegic
storage. A number of substrates are converted into oxi-
dizable intermediates during ischemia. As a conse-
quence of anaerobic breakdown of glycogen, lactate
Fig 3. Schematic presentation of the coupling between glutamate metabolism, glycolysis, and reactions of the cit-
ric acid cycle, indicating the pathways of anaerobic energy formation (A), and oxidative metabolism of glucose
and possible fate of glutamate under aerobic conditions (B). α-KGA, α-Keto-glutarate; ASP, aspartate; ATP,
adenosine triphosphate; CIT, citrate; FUM, fumerate; GTP, guanosine triphosphate; MAL, malate; NAD and
NADH, oxidized and reduced nicotinamide adenine dinucleotide; OAA, oxaloacetate.
A
B
accumulates and glutamate is transaminated to alanine,
which also accumulates in the cytosol.8,27,28 This is in
accordance with our findings of decreasing tissue con-
tent of glycogen, adenosine triphosphate, and gluta-
mate and increasing tissue content of lactate and ala-
nine during 30 hours of cardioplegic storage. More
important, captopril had no effect on any of the mea-
sured metabolites during storage. In particular, we
found no glutamate accumulation, which could explain
the massive glutamate release at the start of reperfu-
sion. The effects of captopril demonstrated in the pres-
ent study are therefore strictly related to the reperfusion
period. The glutamate release at the start of reperfusion
in captopril-treated hearts is most likely caused by
metabolic modulation, as described above.
In conclusion, the present study demonstrates that the
cardioprotective properties of captopril in connection
with cardioplegia and reperfusion are strictly related to
the reperfusion period. The study further demonstrates
that captopril increases glutamate release during reper-
fusion after cardioplegic storage. We suggest that this is
caused by increased myocardial glucose uptake, which
enhances anaplerosis of citric acid cycle intermediates
and enables increased glucose oxidation in captopril-
treated hearts during reperfusion.
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